S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
NYSE:MCK

McKesson (MCK) Stock Price, News & Analysis

$538.28
-0.98 (-0.18%)
(As of 11:09 AM ET)
Today's Range
$535.69
$540.00
50-Day Range
$484.60
$536.09
52-Week Range
$352.34
$540.00
Volume
49,579 shs
Average Volume
727,359 shs
Market Capitalization
$70.74 billion
P/E Ratio
24.39
Dividend Yield
0.46%
Price Target
$522.21

McKesson MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
3.2% Downside
$522.21 Price Target
Short Interest
Healthy
1.23% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
0.69mentions of McKesson in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$8.65 M Sold Last Quarter
Proj. Earnings Growth
12.28%
From $27.61 to $31.00 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.75 out of 5 stars

Medical Sector

51st out of 939 stocks

Drugs, Proprietaries, & Sundries Industry

2nd out of 8 stocks

MCK stock logo

About McKesson Stock (NYSE:MCK)

McKesson Corporation is a prominent player in the healthcare industry, offering a wide range of supply chain management solutions, retail pharmacy services, community oncology and specialty care, and healthcare information technology. With a rich history dating back to 1833, McKesson has established itself as a leading provider of essential healthcare products and services, contributing to the well-being of patients and the efficiency of healthcare providers.

The company's mission is to improve care in every setting, one product, partner, and patient at a time. McKesson operates globally, with a significant presence in the United States, Europe, and Canada, serving a diverse customer base, including hospitals, pharmacies, physician offices, surgery centers, nursing homes, and home health care agencies.

McKesson's operations are organized into several segments. The U.S. Pharmaceutical segment, one of the company's key pillars, is pivotal in distributing a comprehensive range of pharmaceutical drugs, including branded, generic, specialty, biosimilar, and over-the-counter medications. It is a crucial link in the pharmaceutical supply chain, ensuring the timely delivery of essential drugs to pharmacies and healthcare facilities across the United States.

In addition to pharmaceutical distribution, McKesson provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. The company empowers healthcare providers to optimize their practices, enhance patient care and improve overall efficiency by offering financial, operational, and clinical solutions.

McKesson's International segment extends its reach beyond the United States, providing distribution and services to wholesale, institutional, and retail customers in European countries and Canada. This global presence enables the company to leverage its expertise and resources to support healthcare systems and deliver high-quality products and services to a broader market.

The Medical-Surgical Solutions segment focuses on supply distribution, logistics, and other services. By catering to healthcare providers such as physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies, McKesson ensures that critical medical supplies are readily available, enabling efficient and effective patient care.

McKesson's management team is composed of highly experienced professionals who bring a wealth of expertise and strategic vision to the company. Led by Chief Executive Officer and Director Brian Scott Tyler, the team is dedicated to driving McKesson's mission forward. Brian Scott Tyler has been influential in steering the company toward continued growth and success. Under his leadership, McKesson has focused on innovation, strategic partnerships, and operational excellence. With a deep understanding of the healthcare landscape, Tyler has led the company through various challenges and has positioned it as a trusted partner for healthcare providers worldwide.

McKesson has consistently delivered strong financial performance, reflecting its ability to navigate the complexities of the healthcare industry while adapting to changing market dynamics. The company has demonstrated robust revenue growth over the years, driven by its diversified portfolio of products and services.

McKesson operates within the broader healthcare industry, characterized by continuous innovation, regulatory complexities, and a focus on patient care. As one of the largest healthcare distributors, McKesson faces competition from both traditional and emerging players in the market. However, the company's extensive distribution network, strong relationships with healthcare providers, and comprehensive product and service offerings give it a competitive edge.

The healthcare industry is subject to various regulatory and political factors impacting market dynamics. Changes in healthcare policies, reimbursement structures, and drug pricing regulations can significantly affect McKesson's operations. However, the company's deep industry knowledge and expertise enable it to navigate these challenges effectively.

McKesson is well-positioned to capitalize on several growth opportunities in the healthcare industry. One key area of focus is expanding its healthcare information technology solutions. As the digital transformation of the healthcare sector continues, McKesson's investments in technology and data analytics enable it to provide advanced solutions that enhance patient care, optimize workflows and drive operational efficiencies.

While McKesson has a strong market position and a track record of success, it faces certain risks and challenges that should be considered. One significant risk is the evolving regulatory landscape, including changes in healthcare policies and drug pricing regulations. Compliance with these regulations can increase costs and impact the company's profitability.

Additionally, competitive pressures within the healthcare industry require McKesson to continually innovate and differentiate its offerings. The emergence of new market entrants and disruptive technologies could challenge the company's market share and profitability.

The COVID-19 pandemic also introduced unprecedented challenges to the healthcare industry. While the pandemic presented opportunities for McKesson to support the healthcare system with essential supplies and services, it also disrupted healthcare operations and supply chains.

To mitigate these risks, McKesson has implemented robust risk management strategies. The company maintains strong relationships with regulatory bodies, stays abreast of industry trends, and invests in innovation and technology to stay ahead of the competition.

MCK Stock Price History

MCK Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
McKesson Co. (NYSE:MCK) CEO Brian S. Tyler Sells 3,473 Shares
MCK Mar 2024 522.500 put
MCK Mar 2024 530.000 call
See More Headlines
Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/2 Dividend
11/30/2023
Dividend Payable
1/02/2024
Last Earnings
2/07/2024
Ex-Dividend for 4/1 Dividend
2/29/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Dividend Payable
4/01/2024
Next Earnings (Confirmed)
5/07/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
CUSIP
58155Q10
Employees
51,000
Year Founded
1833

Price Target and Rating

Average Stock Price Target
$522.21
High Stock Price Target
$620.00
Low Stock Price Target
$475.00
Potential Upside/Downside
-3.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$3.56 billion
Pretax Margin
1.18%

Debt

Sales & Book Value

Annual Sales
$276.71 billion
Cash Flow
$32.42 per share
Book Value
($10.99) per share

Miscellaneous

Free Float
131,132,000
Market Cap
$70.90 billion
Optionable
Optionable
Beta
0.44

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of McKesson was last updated on Tuesday, March 26, 2024 at 10:26 PM.

Pros

Here are some ways that investors could benefit from investing in McKesson Co.:

  • McKesson Co. operates in the healthcare services industry, which is known for its stability and consistent demand, making it a reliable investment option.
  • The company's diverse segments, including U.S. Pharmaceutical, Prescription Technology Solutions, and International, provide a broad revenue base, reducing risk associated with dependency on a single market.
  • Recent insider buying activities, such as CEO Brian S. Tyler purchasing shares, can indicate confidence in the company's future performance, which may be a positive signal for investors.
  • McKesson's strategic focus on innovative solutions to improve medication access and delivery can position the company well in the evolving healthcare landscape, potentially driving future growth.
  • Considering the current stock price and market conditions, McKesson Co. may be undervalued compared to its intrinsic value, presenting a potential opportunity for value investors.

Cons

Investors should be bearish about investing in McKesson Co. for these reasons:

  • McKesson Co. faces regulatory risks associated with the healthcare industry, including changes in government policies and regulations, which could impact the company's operations and financial performance.
  • The competitive landscape in the healthcare distribution sector is intense, with the presence of other major players, leading to pricing pressures and potential margin squeezes for McKesson.
  • Recent insider selling activities, like CEO Brian S. Tyler selling shares, may raise concerns among investors about the company's future prospects or potential challenges ahead.
  • Fluctuations in pharmaceutical pricing and reimbursement policies could affect McKesson's profitability, especially in the U.S. Pharmaceutical segment, which is a significant revenue contributor.
  • The ongoing global health crisis and its economic impacts may pose uncertainties for McKesson Co.'s business operations and financial results in the near term.

MCK Stock Analysis - Frequently Asked Questions

Should I buy or sell McKesson stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MCK shares.
View MCK analyst ratings
or view top-rated stocks.

What is McKesson's stock price target for 2024?

12 equities research analysts have issued 12 month price objectives for McKesson's stock. Their MCK share price targets range from $475.00 to $620.00. On average, they expect the company's stock price to reach $522.21 in the next twelve months. This suggests that the stock has a possible downside of 3.2%.
View analysts price targets for MCK
or view top-rated stocks among Wall Street analysts.

How have MCK shares performed in 2024?

McKesson's stock was trading at $462.98 at the start of the year. Since then, MCK stock has increased by 16.5% and is now trading at $539.51.
View the best growth stocks for 2024 here
.

When is McKesson's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our MCK earnings forecast
.

How were McKesson's earnings last quarter?

McKesson Co. (NYSE:MCK) posted its quarterly earnings data on Wednesday, February, 7th. The company reported $7.74 earnings per share for the quarter, topping analysts' consensus estimates of $7.05 by $0.69. The company had revenue of $80.90 billion for the quarter, compared to analyst estimates of $77.93 billion. McKesson had a net margin of 0.99% and a negative trailing twelve-month return on equity of 262.63%. The firm's revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.90 EPS.
Read the conference call transcript
.

How often does McKesson pay dividends? What is the dividend yield for McKesson?

McKesson announced a quarterly dividend on Thursday, February 1st. Shareholders of record on Friday, March 1st will be paid a dividend of $0.62 per share on Monday, April 1st. This represents a $2.48 annualized dividend and a yield of 0.46%. The ex-dividend date is Thursday, February 29th.
Read our dividend analysis for MCK
.

Is McKesson a good dividend stock?

McKesson (NYSE:MCK) pays an annual dividend of $2.48 per share and currently has a dividend yield of 0.46%. The company has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 11.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MCK will have a dividend payout ratio of 8.00% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MCK.

What guidance has McKesson issued on next quarter's earnings?

McKesson updated its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided earnings per share (EPS) guidance of 27.250-27.650 for the period, compared to the consensus earnings per share estimate of 27.320. The company issued revenue guidance of $307.1 billion-$315.5 billion, compared to the consensus revenue estimate of $305.3 billion.

What is Brian Tyler's approval rating as McKesson's CEO?

220 employees have rated McKesson Chief Executive Officer Brian Tyler on Glassdoor.com. Brian Tyler has an approval rating of 88% among the company's employees.

What other stocks do shareholders of McKesson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Gilead Sciences (GILD), CVS Health (CVS), AbbVie (ABBV), Bank of America (BAC), AT&T (T), JPMorgan Chase & Co. (JPM), UnitedHealth Group (UNH) and Home Depot (HD).

Who are McKesson's major shareholders?

McKesson's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.24%), Massachusetts Financial Services Co. MA (3.78%), Viking Global Investors LP (1.70%), Norges Bank (1.66%), Putnam Investments LLC (1.52%) and Price T Rowe Associates Inc. MD (1.40%). Insiders that own company stock include Brian S Tyler, Brian S Tyler, Britt J Vitalone, Kevin Emerson, Leann B Smith, Lori A Schechter, Lori A Schechter, Nancy Avila, Nancy Flores, Sundeep G Reddy, Thomas L Rodgers, Thomas L Rodgers and Tracy Faber.
View institutional ownership trends
.

How do I buy shares of McKesson?

Shares of MCK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does McKesson have any subsidiaries?
The following companies are subsidiares of McKesson: A.L.I. Technologies, AMISYS Managed Care Systems, Abaton.com, Access Health, Biologics, Celesio, CoverMyMeds, D & K Healthcare Resources, Drug Trading Co. Ltd., EN-Chart Scanning Program, Echo, Emendo, Enterprise Systems Inc., HBO & Company, HPR, HealthCom Partners, HealthQx, IMNET Systems, LloydsDirect, MED3000, McKesson Europe AG, McKesson Europe Holdings GmbH & Co. KGaA, McKesson Global Procurement & Sourcing Limited, McKesson International Bermuda IP2A Limited, McKesson International Bermuda IP3A Limited, McKesson Ireland Limited, McKesson Medical-Surgical Holdings Inc., McKesson Medical-Surgical Inc., McKesson Medical-Surgical Supply Chain Services LLP, McKesson Medical-Surgical Top Holdings Inc., McKesson Plasma and Biologics LLC, McKesson Specialty Care Distribution LLC, McKesson UK Finance I Limited, McKesson UK Finance II Limited, McKesson US Finance Corporation, McQueary Brothers, MedVentive, Medcon, MediVation Inc., Medical Specialties Distributors, Medis Health And Pharmaceutical Services, Moore Medical, NDCHealth, Oncology Therapeutics Network, PSS World Medical, Per-Se Technologies, Portico Systems, Practice Partner, RedLine HealthCare, RelayHealth, Rexall, Rosebud Solutions, RxCrossroads, Sterling Medical Services LLC, UDG Healthcare, US Oncology, US Oncology Holdings Inc., US Oncology Inc., United Drug (Wholesale) Limited, United Drug Distributors Ireland Limited, Vantage Oncology, Vivalog Technologies, Well.ca, and peerVue.
Read More
This page (NYSE:MCK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners